Study of novel 1,4-benzodiazepine analogue as analgesic targeting by molecular docking

Abstract

Benzodiazepines (BZDs) are one of the most widely prescribed pharmacologic agents in the world. BZDs are used for numerous indications, including anxiety, insomnia, muscle relaxation, relief from spasticity caused by central nervous system pathology, and epilepsy. BZDs are also used intraoperatively because of their amnesic and anxiolytic properties. However, these properties become undesired side effects in nearly all other clinical instances. Propoxazepam, 7-bromo-5 - (o-chlorophenyl)-3-propoxy - 1,2-dihydro - 3H-1,4-benzodiazepin-2-one, in the models of nociceptive and neuropathic pain showed significant analgesic activity. Similar to gabapentin and pregabalin, which are well-known anti-epileptic drugs used in general medical practice in the treatment of neuropathic pain, propoxazepam also has an anticonvulsant effect, which explains the analgesic component of the pharmacological spectrum. Both oral and intraperitoneally preparations are similar in activity, although intraperitoneally administration is preferred. It has proven in in vivo studies to be the potent drug in its class against acute and chronic pain.